Dear Dinesh, Small, Priyansh, Splendid It compete with Pantamoth Par drugs So this issue very difficult to sail through. Its book value is just 13 but issue price is 65. Now company looks like skeleton because it utilized all reserves as bonus. Before bonus issue it is fantastic company. Now company requires two to three years to build Balance Sheet strong. We are listing gainers so it may be skip. If HNI subscribes more than 4 times then we consider it..
Very well managed business. Management is confident of reporting 30% CAGR growth.
Key concerns are: issuing at high PE, 7cr acquisition of sister company (we don't have info on valuation). And 45cr debt on book. I think this will open above offer price. Let see how many time it receive over subscription.
Dear Members Skip all sme which is hni subscribed 2 times to sail through. Wait for Pantamoth. If any company hni subscribes more than 4 times then we consider. I already told all sme listed at par or will listing at par, will not be useful for listing gainer like me. So skip all sme ipo.
16. jajo| Link| Bookmark|
April 25, 2019 11:21:08 AM
Top Contributor (300+ Posts, 200+ Likes)
Here's a request to please give us the names of some stock brokers who are dealing in SME listed shares. This information will be useful to many investors. Thanks in advance.
Rajkumar Starlite Components of Nasik is exact peer to Artimies. Visited both plants two Years back. Artimies had good infrastructure that time. Currently not aware of.
Met the owner and management team below are the comments from which I feel is rationale
CIAN healthcare is aquiring Dr. Smith biotech private limited from promotors at the pure book value investment and No premium or interest is calculated on investment.
The motive to acquire the plant is to add new line of business ie softgel manufacturing facility in the existing company, which will be an added business line for nutracuitical business of the company. This plant is a state of art manufacturing facility located in haridwar which is at par with international standards.
Acquisition of plant will also help promoters to concentrate on the business of CIAN only and management bandwidth will be fully devoted for devlopment of CIAN.
Dear Dinesh 31 Mar 2018 Eps is 2.3 Sep. 30 2018 is Rs.2,3 (If annualised means around 6 Eps on Mar 2019) RONW 22.5% as on 31Mar 2018 NAV 122 as on 31 Mar 2018 and 159 as on Sep 2018 (Pre Bonus) Post Bonus Nav is Just Rs. 13 as on 30 Sep. 2018. Company utilised all reserves as bonus before public issue. Deccan trading 12 pe Zota trading 62 pe Sakar 21 pe Jenburkt 12 pe (DRHP PAGE 96) According to Splendid it coming at Rs. 65 so it oomes at par with Deccan. Firrst Look seems not ok . LM is Fedex. Shareholders Fund 22Cr. But Long Term Borrowings 24Cr. and Short Term Borrowing 20 Cr. So Total borrowing 45 Cr. Debt Equity Ratio is 2:1 In Sme stock we can not predict which stock going to list with premium.
Dear Small Dinesh, splendid, Pryanka Meghwal Suich Ind coming this month end. LM Pantamoth. Pantamoth other issues lined up Gensol eng Preeti Remedies MDC